Back to Search
JAMES PATTI, M.D.
M.D.
Orthopaedic Surgery Physician
NPI: 1336296441IndividualAccepts Medicare
Specialties, Licenses & Credentials
Orthopaedic Surgery PhysicianPrimary
Orthopaedic Surgery
Code: 207X00000X
25MA06731300(NJ)
CMS Specialties
PrimaryORTHOPEDIC SURGERY
Education
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
Class of 1992
Research & Publications (20)
Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies.
PMID 19157788·Schizophr Res·2009
8-other
Monoclonal antibodies specific for Candida albicans Als3 that immunolabel fungal cells in vitro and in vivo and block adhesion to host surfaces.
PMID 19427882·J Microbiol Methods·2009
7-preclinical
ACR white paper: the value added that radiologists provide to the health care enterprise.
PMID 18812148·J Am Coll Radiol·2008
8-other
Impingement of lesser trochanter on ischium as a potential cause for hip pain.
PMID 18682931·Skeletal Radiol·2008
5-case
The economic environment of 2006: how safe is your practice and what you can do to protect it.
PMID 17412239·J Am Coll Radiol·2007
8-other
Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants.
PMID 17719934·J Pediatr·2007
2-rct
A panel of monoclonal antibodies recognizing the Staphylococcus epidermidis fibrinogen-binding MSCRAMM SdrG.
PMID 17316083·Hybridoma (Larchmt)·2007
7-preclinical
Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo.
PMID 16436704·Antimicrob Agents Chemother·2006
7-preclinical
Using biological inspiration to engineer functional nanostructured materials.
PMID 17192981·Small·2006
7-preclinical
Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.
PMID 17005843·Antimicrob Agents Chemother·2006
3-trial
Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.
PMID 16870768·Antimicrob Agents Chemother·2006
3-trial
Physician collaboration with payers: an important step on the road to optimum patient care.
PMID 17412037·J Am Coll Radiol·2006
6-review
Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.
PMID 16041045·Infect Immun·2005
7-preclinical
Vaccines and immunotherapy for staphylococcal infections.
PMID 16353122·Int J Artif Organs·2005
6-review
Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants.
PMID 16220082·Pediatr Infect Dis J·2005
3-trial
Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants.
PMID 16189088·Antimicrob Agents Chemother·2005
8-other
Role of Staphylococcus aureus global regulators sae and sigmaB in virulence gene expression during device-related infection.
PMID 15908369·Infect Immun·2005
7-preclinical
Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.
PMID 15728889·Antimicrob Agents Chemother·2005
3-trial
A comparison of epidemiologic and immunologic features of bronchiolitis caused by influenza virus and respiratory syncytial virus.
PMID 15602730·J Med Virol·2005
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10 PARSONAGE RD STE 500
EDISON, NJ 08837 - Phone
- (732) 494-6226
Quick Facts
- NPI
- 1336296441
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile